Literature DB >> 17988152

Enantiomers of 4-amino-3-fluorobutanoic acid as substrates for gamma-aminobutyric acid aminotransferase. Conformational probes for GABA binding.

Michael D Clift1, Haitao Ji, Gildas P Deniau, David O'Hagan, Richard B Silverman.   

Abstract

Gamma-aminobutyric acid aminotransferase (GABA-AT), a pyridoxal 5'-phosphate dependent enzyme, catalyzes the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) to succinic semialdehyde with concomitant conversion of pyridoxal 5'-phosphate (PLP) to pyridoxamine 5'-phosphate (PMP). The enzyme then catalyzes the conversion of alpha-ketoglutarate to the excitatory neurotransmitter L-glutamate. Racemic 4-amino-3-fluorobutanoic acid (3-F-GABA) was shown previously to act as a substrate for GABA-AT, not for transamination, but for HF elimination. Here we report studies of the reaction catalyzed by GABA-AT on (R)- and (S)-3-F-GABA. Neither enantiomer is a substrate for transamination. Very little elimination from the (S)-enantiomer was detected using a coupled enzyme assay; The rate of elimination of HF from the (R)-enantiomer is at least 10 times greater than that for the (S)-enantiomer. The (R)-enantiomer is about 20 times more efficient as a substrate for GABA-AT catalyzed HF elimination than GABA is a substrate for transamination. The (R)-enantiomer also inhibits the transamination of GABA 10 times more effectively than the (S)-enantiomer. Using a combination of computer modeling and the knowledge that vicinal C-F and C-NH3+ bonds have a strong preference to align gauche rather than anti to each other, it is concluded that on binding of free 3-F-GABA to GABA-AT the optimal conformation places the C-NH3+ and C-F bonds gauche in the (R)-enantiomer but anti in the (S)-enantiomer. Furthermore, the dynamic binding process and the bioactive conformation of GABA bound to GABA-AT have been inferred on the basis of the different biological behavior of the two enantiomers of 3-F-GABA when they bind to the enzyme. The present study suggests that the C-F bond can be utilized as a conformational probe to explore the dynamic binding process and provide insight into the bioactive conformation of substrates, which cannot be easily determined by other biophysical approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988152      PMCID: PMC2570590          DOI: 10.1021/bi701249q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  42 in total

1.  The NH---FC dipole orientation effect for pendant exocyclic CH(2)F.

Authors:  David C Lankin; Gary L Grunewald; F Anthony Romero; Ilkay Yildiz Oren; James P Snyder
Journal:  Org Lett       Date:  2002-10-17       Impact factor: 6.005

Review 2.  GABA and epileptogenesis.

Authors:  R W Olsen; M Avoli
Journal:  Epilepsia       Date:  1997-04       Impact factor: 5.864

3.  Evidence of a borderline region between E1cb and E2 elimination reaction mechanisms: a combined experimental and theoretical study of systems activated by the pyridine ring.

Authors:  Sergio Alunni; Filippo De Angelis; Laura Ottavi; Magdalini Papavasileiou; Francesco Tarantelli
Journal:  J Am Chem Soc       Date:  2005-11-02       Impact factor: 15.419

Review 4.  Functional implications of neurotransmitter co-release: glutamate and GABA share the load.

Authors:  Rebecca P Seal; Robert H Edwards
Journal:  Curr Opin Pharmacol       Date:  2005-12-15       Impact factor: 5.547

Review 5.  The GABA shunt: an attractive and potential therapeutic target in the treatment of epileptic disorders.

Authors:  P Yogeeswari; D Sriram; J Vaigundaragavendran
Journal:  Curr Drug Metab       Date:  2005-04       Impact factor: 3.731

6.  Syntheses of (Z)-and (E)-4-amino-2-(trifluoromethyl)-2-butenoic acid and their inactivation of gamma-aminobutyric acid aminotransferase.

Authors:  T R Johnson; R B Silverman
Journal:  Bioorg Med Chem       Date:  1999-08       Impact factor: 3.641

7.  Mechanistic crystallography. Mechanism of inactivation of gamma-aminobutyric acid aminotransferase by (1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid as elucidated by crystallography.

Authors:  Paola Storici; Jian Qiu; Tilman Schirmer; Richard B Silverman
Journal:  Biochemistry       Date:  2004-11-09       Impact factor: 3.162

8.  Inactivation of gamma-aminobutyric acid aminotransferase by (S,E)-4-amino-5-fluoropent-2-enoic acid and effect on the enzyme of (E)-3-(1-aminocyclopropyl)-2-propenoic acid.

Authors:  R B Silverman; B J Invergo; J Mathew
Journal:  J Med Chem       Date:  1986-10       Impact factor: 7.446

Review 9.  An update on GABA analogs for CNS drug discovery.

Authors:  Perumal Yogeeswari; Jegadeesan Vaigunda Ragavendran; Dharmarajan Sriram
Journal:  Recent Pat CNS Drug Discov       Date:  2006-01

10.  Inactivation of gamma-aminobutyric acid aminotransferase by (Z)-4-amino-2-fluorobut-2-enoic acid.

Authors:  R B Silverman; C George
Journal:  Biochemistry       Date:  1988-05-03       Impact factor: 3.162

View more
  3 in total

1.  The C-F bond as a conformational tool in organic and biological chemistry.

Authors:  Luke Hunter
Journal:  Beilstein J Org Chem       Date:  2010-04-20       Impact factor: 2.883

2.  Highly Diastereoselective Construction of Carbon- Heteroatom Quaternary Stereogenic Centers in the Synthesis of Analogs of Bioactive Compounds: From Monofluorinated Epoxyalkylphosphonates to α-Fluoro-, β-, or γ-Amino Alcohol Derivatives of Alkylphosphonates.

Authors:  Magdalena Rapp; Klaudia Margas-Musielak; Patrycja Kaczmarek; Agnieszka Witkowska; Tomasz Cytlak; Tomasz Siodła; Henryk Koroniak
Journal:  Front Chem       Date:  2021-06-02       Impact factor: 5.221

3.  Turnover and Inactivation Mechanisms for (S)-3-Amino-4,4-difluorocyclopent-1-enecarboxylic Acid, a Selective Mechanism-Based Inactivator of Human Ornithine Aminotransferase.

Authors:  Sida Shen; Arseniy Butrin; Peter F Doubleday; Rafael D Melani; Brett A Beaupre; Mauricio T Tavares; Glaucio M Ferreira; Neil L Kelleher; Graham R Moran; Dali Liu; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2021-06-07       Impact factor: 16.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.